– Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura...
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Seaking AlphaSeeking Alpha / Seaking Alpha 9 hours ago 1 Views
Comments